Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer |
| |
| Authors: | Tanja N. Fehm,Manfred Welslau,Volkmar Mü ller,Diana Lü ftner,Florian Schü tz,Peter A. Fasching,Wolfgang Janni,Christoph Thomssen,Isabell Witzel,Milena Beierlein,Erik Belleville,Michael Untch,Marc Thill,Hans Tesch,Nina Ditsch,Michael P. Lux,Bahriye Aktas,Maggie Banys-Paluchowski,Cornelia Kolberg-Liedtke,Andreas D. Hartkopf,Achim Wö ckel,Hans-Christian Kolberg,Nadia Harbeck,Elmar Stickeler |
| |
| Abstract: | ![]()
The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.Key words: breast cancer, surgery, chemotherapy, therapy standard |
| |
| Keywords: | |
|
|
